interferon – Page 34 – Communicable Diseases Research

Inter-individual Variation in Receptor Expression Influences MERS-CoV Infection and Immune Responses in Airway Epithelia

Public Health

Published on 2022-01-042022-10-31
Journal: Frontiers in Public Health [Category] COVID-19,

The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet’s syndrome

전향적으로 추적한 베체트 증후군 환자 코호트에서 COVID-19의 발병률, 임상적 특징 및 결과

Article

Published on 2022-01-012022-09-11
Journal: Rheumatology International [Category] 치료제,

[키워드] 95% CI adjusted age and gender Anosmia Anticoagulants arthralgia Asymptomatic Behcet's disease case sery Clinical characteristics Clinical outcome Cohort cohort of patient Colchicine Complete COVID-19 COVID-19 infection cumulative cumulative incidence defined died disease course dose drug discontinuation exacerbate fatigue Favipiravir Fever Follow-up followed by General population headache Hospitalized Hydroxychloroquine immunosuppressive incidence incidence of COVID-19 indicated infected with SARS-CoV-2 Infection information intensive care intensive care unit interferon interferon-alpha İstanbul laboratory-confirmed large cohort likelihood lung involvement management median Mortality Multiple Multiple regression analysis not differ outcome outpatient clinic pandemic Patient patients PCR positive positive Prognosis Prospective Study protective effect Registered regression analysis remaining reported SARS-CoV-2 SARS-CoV-2 PCR severity of COVID-19 Significant significantly smoking Symptom syndrome tested the patient thrombotic thrombotic event Thrombotic events took place Treatment Turkey were given
[DOI] 10.1007/s00296-021-05056-2 PMC 바로가기 [Article Type] Article

Humoral and Cellular Immune Responses to SARS-CoV-2 Infection and Vaccination in Autoimmune Disease Patients With B Cell Depletion

B 세포 고갈이 있는 자가 면역 질환 환자의 SARS-CoV-2 감염 및 예방 접종에 대한 체액 및 세포 면역 반응

Article

Published on 2022-01-012022-09-11
Journal: Arthritis & rheumatology (Hoboken, N.J.) [Category] SARS, 치료법,

[키워드] antibodies Antibody Response Antibody responses Autoimmune disease autoimmune disease patient Autoimmune diseases B cell B cells block Cellular immune response Control controls Critical Depletion enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay enzyme-linked immunospot assay expected healthy control healthy controls humoral Humoral and cellular immune responses humoral immune response immune responses Infection interferon interferon-γ nucleocapsid nucleocapsid protein Nucleocapsid proteins Patient protective immunity response SARS-CoV-2 SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 vaccination T cell T cell response T cell responses tested the patient the SARS-CoV-2 therapeutic These data vaccination were assessed
[DOI] 10.1002/art.41914 PMC 바로가기 [Article Type] Article

T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study

이전에 감염된 SARS-CoV-2-naive 영국 의료 종사자의 첫 BNT162b2 백신 투여에 대한 T 세포 및 항체 반응: 다기관 전향적 코호트 연구

Multicenter Study

Published on 2022-01-012022-09-10
Journal: The Lancet. Microbe [Category] MERS, SARS, 변종, 진단, 치료법,

[키워드] Affect All participants Analysis anti-SARS-CoV-2 antibodies antibody Antibody Response antibody unit Antibody Units applied benefit blood sample Blood samples BNT162b2 BNT162b2 vaccine collected coronavirus cryopreserved PBMCs Department determine determined by dose doses enrolled enzyme-linked immunospot assay exclusion criteria finding first dose fresh peripheral blood mononuclear cells funding Future greater health-care hospital IgG antibodies IgG antibody immune response immune responses individual individuals infected individual Infection infection with SARS-CoV-2 interferon interferon-γ IQR magnitude median median time mononuclear cell mononuclear cells mRNA vaccine multicentre naïve individuals nucleocapsid Older Oxford participant PBMCs Peripheral blood Peripheral blood mononuclear cells Pfizer–BioNTech positive prospective cohort study quantified receiving response RT-PCR SARS-COV-2 infection SARS-CoV-2 vaccine second dose single dose specific IgG antibodies Specific T-cell response spike-specific IgG spike-specific IgG antibodies spike-specific T-cell response spot spot-forming unit spot-forming units T-cell T-cell Response T-cell responses the median the SARS-CoV-2 vaccination Vaccine vaccine dose vaccine doses variants variants of concern was determined
[DOI] 10.1016/S2666-5247(21)00275-5 PMC 바로가기 [Article Type] Multicenter Study

Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis

다발성 경화증 환자에서 BNT162b2 mRNA 백신 2회 접종 후 코로나19 혈청학적 반응에 대한 클라드리빈의 효과

Article

Published on 2022-01-012022-09-12
Journal: Multiple sclerosis and related disorders [Category] MERS, SARS, 진단,

Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint

Covid-19 Pandemic 동안 다발성 경화증 치료에 사용되는 약물 : 중요한 관점

Article

Published on 2022-01-012022-08-31
Journal: Current neuropharmacology [Category] SARS, 치료제,

[키워드] Acetate activating acute respiratory distress acute respiratory distress syndrome Alemtuzumab analogue antiviral activity approved ARDS autoimmune disorder Autoimmune disorders caution cellular Cladribine concern COVID-19 COVID-19 infection COVID-19 pandemic cytokine Cytokine storm Defense depleting detrimental dimethyl fumarate disease Disease-modifying therapy drug early stage endothelial example fingolimod fumarate Glatiramer Glatiramer acetate health problem hyperinflammation Hyperinflammatory IFN IFNs immunomodulation interfere interferon Invasion lung Macrophage mechanisms Multiple multiple sclerosis Natalizumab neuroprotection Nrf-2 nucleotide nucleotides Ocrelizumab other organs overcome oxidative stress pathway potential risk Protective public health raised reinforcement respiratory distress risk risk-benefit ratio. Safe SARS-CoV-2 SARS-COV-2 infection sclerosis suggested syndrome Teriflunomide Treatment Viral viral replication
[DOI] 10.2174/1570159X19666210330094017 PMC 바로가기 [Article Type] Article

A Case of Autosomal Recessive Interferon Alpha/Beta Receptor Alpha Chain (IFNAR1) Deficiency with Severe COVID-19

중증 코로나19를 동반한 상염색체 열성 인터페론 알파/베타 수용체 알파 사슬(IFNAR1) 결핍 1예

Case Reports

Published on 2022-01-012022-09-11
Journal: Journal of Clinical Immunology [Category] 치료제,

[키워드] Admission Antibiotics antiviral immunity Auto-antibodies auto-antibody both lungs chain Computed tomography consolidation coronavirus COVID-19 diagnosed discharged Favipiravir Fever form general condition genetic defects homozygous hospital HRCT hypoxemic IFN IFN-α IFN-α/β IFN-γ IFNAR1 IFNAR1 deficiency IFNs Infectious disease Infectious diseases intensive care interferon interferon gamma Interferon-gamma interferons interferons (IFNs) life-threatening loss-of-function loss-of-function mutation lung involvement Lungs medication Methylprednisolone Mutation Patient pediatric pulse receptor receptors recessive Remdesivir reported SARS-CoV-2 severe COVID-19 severe forms of COVID-19 Side effect signaling pathway signaling pathways subunit Symptom the patient therapy treat
[DOI] 10.1007/s10875-021-01166-5 PMC 바로가기 [Article Type] Case Reports

Resolution of viral load in mild COVID-19 patients is associated with both innate and adaptive immune responses

경증 COVID-19 환자의 바이러스 부하 해결은 선천 면역 반응 및 적응 면역 반응 모두와 관련이 있습니다

Article

Published on 2022-01-012022-09-11
Journal: Journal of Clinical Virology [Category] SARS, 변종, 신약개발, 유전자 메커니즘, 진단, 치료기술,

[키워드] absence acute phase Adaptive immune response all the patients antibodies antibody Asymptomatic characterized circulating collected Comorbidities Comorbidity COVID-19 COVID-19 patient COVID-19 patients Cytokines detectable dysregulation Efficiency elevated Factor had no hospitalized COVID-19 patient Host IgG IL-1β IL-6 IL-7 IL-8 immune response implicated in viral increase in Inflammation Inflammatory cytokine Inflammatory cytokines inflammatory mediator Inflammatory mediators innate immune response interferon Kinetics marker mediators mild COVID-19 patient mild infection Mild symptom mild symptoms Most patient Most patients neutralize Neutralizing antibodies neutralizing antibody no increase over Patient PRNT Receptor-binding domain Resolution respiratory respiratory sample Respiratory samples Saliva saliva samples SARS-CoV-2 SARS-CoV-2 viral load Seroconversion serum serum samples severe COVID-19 strain swab samples Symptom T-cell activation the patient the receptor-binding domain These data TNF-α Viral Viral load Viral RNA viral RNA detection virus isolate Virus neutralization
[DOI] 10.1016/j.jcv.2021.105060 PMC 바로가기 [Article Type] Article

NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects

NSAIDS/NITAZOXANIDE/AZITHROMYCIN COVID-19에 대한 용도 변경 : 면역 조절 효과를 통한 사이토 카인 폭풍 인터루킨 -6 앰프의 잠재적 완화

Article

Published on 2022-01-012022-08-31
Journal: Expert review of anti-infective therapy [Category] MERS, SARS, 신약개발,

[키워드] Anti-inflammatory approach Area Aspirin Author Azithromycin benefit best Clinical studies clinical trials clinically Colchicine Combination Complication correlated COVID-19 COVID-19 complication COVID-19 complications COVID-19 pathogenesis COVID-19 patient COVID-19 patients Cytokines demonstrated Diclofenac double blind drug dysregulated dysrhythmia Effect expert Genetic ibuprofen IL-6 IL-6 amplifier Immunity immunological immunomodulatory effect immunomodulatory properties Inflammation Inflammatory response Inflammatory responses interferon interferon response interferons interleukin-6 low-dose management mediator mediators monocytic immunological dysrhythmia Mortality NF-kB nitazoxanide nitazoxanide. Non-steroidal anti-inflammatory drugs NSAIDS observational study Paracetamol positive Prevent randomized clinical trials researcher selected suggested survival the cytokine storm
[DOI] 10.1080/14787210.2021.1939683 PMC 바로가기 [Article Type] Article

A virus-specific monocyte inflammatory phenotype is induced by SARS-CoV-2 at the immune–epithelial interface

420

Published on 2021-12-282022-10-29
Journal: Proceedings of the National Academy of Sciences of [Category] COVID-19,

[키워드] acute respiratory syndrome age B cells Blood children Coronavirus-2 COVID-19 COVID-19 patients cross-talk Cytokine storm deviation Ebola elicit encodes epithelia epithelial epithelial cell Express Factors fraction gene cluster hallmark healthy children Immune cell immune cells immune dysregulation induce infected with SARS-CoV-2 Inflammatory inflammatory phenotype influenza A initial Interaction interferon lung manifestation monocyte multiorgan failure myeloid cell nonstructural proteins pathogenic viruses Patient Perturbation Pneumonia Protein provide provoke reported SARS-CoV-2 SARS-CoV-2 protein severe COVID-19 severe disease Significance spike systemic inflammation transcriptional transduced virus
[DOI] 10.1073/pnas.2116853118 PMC 바로가기 [Article Type] 420